In this project, structural MRI data will be obtained at baseline from controls and non-demented subjects with cognitive impairments who will be recruited through the Clinical Core and followed over time. Subjects will be evaluated longitudinally with MRI when they cross specific transition boundaries, as defined by the Clinical Core. The overall goal of the MRI project is to determine whether structural MRI data can be used to predict which non-demented individuals with cognitive problems will develop progressive cognitive decline, which will progress to the point where they meet criteria for AD, and which will remain stable. In addition, we will seek to determine the evolution of brain changes that characterize prodromal AD, and how these measures relate to the clinical characteristics of the subjects. Underlying these goals is the assumption that structural MRI data can serve as an indirect measure of the neuronal loss that occurs when neuritic plaques and neurofibrillary tangles accumulate during the development of Alzheimer's disease (AD). In the proposed funding cycle we will use manually drawn regions of interest (R01), as we have done in the past, to evaluate atrophy in selected brain regions. We are also proposing to enhance and apply a new automated method for identifying ROIs automatically, and to compare this method to the manual measurements. Both types of MRI data will e used by other projects in the Program Project, and thus an additional responsibility of this Project is to distribute MRI images, and regions of interest derived from them, to investigators in Project by Johnson (SPECT) and Project by Sperling (fMRI). In addition, we will seek to determine the relationship between SPECT measures and other information obtained on the same individuals by the cores and the projects, including clinical data, genotype status, volumetric MRI, and fMRI signal change.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG004953-19
Application #
6548804
Study Section
Special Emphasis Panel (ZAG1-FAS-3 (M1))
Project Start
1984-08-01
Project End
2007-07-31
Budget Start
Budget End
Support Year
19
Fiscal Year
2002
Total Cost
$371,695
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
D'Avanzo, Carla; Aronson, Jenna; Kim, Young Hye et al. (2015) Alzheimer's in 3D culture: challenges and perspectives. Bioessays 37:1139-48
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Liang, Steven H; Yokell, Daniel L; Jackson, Raul N et al. (2014) Microfluidic continuous-flow radiosynthesis of [(18)F]FPEB suitable for human PET imaging. Medchemcomm 5:432-435
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Johnson, Keith A; Sperling, Reisa A; Gidicsin, Christopher M et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72-83
Fung, Wai Lun Alan; Naylor, Melissa G; Bennett, David A et al. (2013) Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. Am J Med Genet B Neuropsychiatr Genet 162B:770-8

Showing the most recent 10 out of 104 publications